Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

157.14USD
16 Feb 2018
Change (% chg)

$-0.04 (-0.03%)
Prev Close
$157.18
Open
$156.62
Day's High
$159.21
Day's Low
$156.62
Volume
56,131
Avg. Vol
84,700
52-wk High
$170.27
52-wk Low
$95.21

Chart for

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $2,981.39
Shares Outstanding(Mil.): 21.05
Dividend: --
Yield (%): --

Financials

BRIEF-Ferring Says Specific Financial Details Of Transaction With Ligand Pharma Are Not Disclosed​

* FERRING ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH LIGAND

22 Jan 2018

BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS

22 Jan 2018

BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS

11 Jan 2018

BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects

* LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS

03 Jan 2018

BRIEF-Ligand Pharmaceuticals - Expects Reduction Of Corporate Tax Rate To Reduce Deferred Tax Asset On Balance Sheet By About $40 Mln

* LIGAND PHARMACEUTICALS - EXPECTS REDUCTION OF CORPORATE TAX RATE TO REDUCE DEFERRED TAX ASSET ON BALANCE SHEET BY ABOUT $40 MILLION AS OF SEPT 30, 2017 Source text: (http://bit.ly/2zy8ap7) Further company coverage:

26 Dec 2017

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​

15 Nov 2017

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

* Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​

13 Nov 2017

BRIEF-Ligand Q3 adjusted earnings per share $0.69

* Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S

10 Nov 2017

BRIEF-Ligand to acquire Crystal Bioscience

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments

05 Oct 2017

BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

* Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

05 Sep 2017

Earnings vs. Estimates